MRI Interventions to Exhibit Its ClearPoint(R) Neuro Navigation System for SNO/SCIDOT Joint Conference on Therapeutic Delivery to the CNS
IRVINE, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint Neuro Navigation System will be at the Society for Neuro-Oncology (SNO) and the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT) Joint Conference on Therapeutic Delivery to the CNS – November 18th and 19th, 2015, in San Antonio, TX. Attendees are invited to visit the MRI Interventions exhibit to learn about the use of the ClearPoint Neuro Navigation System for monitoring convection enhanced drug delivery (CED).
"The ClearPoint Neuro Navigation System provides MRI guidance and placement of catheters for drug infusion into the brain allowing clinicians to directly monitor distribution of therapeutics under real-time, MRI visualization. Any reflux along the CED catheter or leakage outside the target area, can be visualized and corrective steps taken and confirmed almost immediately." said, Krystof Bankiewicz, M.D., Ph.D., Professor of Neurosurgery and Neurology, Kinetics Foundation Chair in Translational Research, University of California San Francisco.
The ClearPoint neuro navigation system allows surgeons to plan, target, and adjust trajectories under real time MRI-guided visualization for placement of electrodes, catheters and biopsy needles.
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. The ClearPoint system, which has received 510(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of our products; our ability to successfully expand, and achieve full productivity from, our sales, clinical support and marketing capabilities; our ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of our cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact our commercialization efforts. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2014, as well as the Company's Form 10-Q for the quarter ended September 30, 2015, which have been filed with the Securities and Exchange Commission.
CONTACT: Wendelin Maners, VP, Marketing MRI Interventions, Inc. 900-949-6833